Emergent BioSolutions Inc. (EBS)
- Sector
- Biotechnology
- Last price
- $6.06
- As of
Kresmion compiles this page from EBS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Emergent BioSolutions Inc. (EBS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.
See the full EBS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EBS on one page. Preview it with sample data, then open it live with a free account.
Preview the EBS dossierActive events for EBS
- mediumEarnings above estimates
Q3-2026: Beat consensus by 8.6%, EPS $-0.36 vs $-0.3939 estimate
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +102% to EBS (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 440.1%, EPS $0.60 vs $0.1111 estimate
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +124% to EBS (2026Q1)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +123% to EBS (2026Q1)
FREE, NO ACCOUNT
Every event on EBS, as it fires
You are seeing 5 of 9 events recorded on EBS since 2026-05-24.
The five above landed across 4 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
EBS positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC FundCUSIP 29089Q105 · 2026Q2 | $9M | 0.01% |
| D. E. Shaw & Co., Inc. FundCUSIP 29089Q105 · 2026Q2 | $7.5M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 29089Q105 · 2026Q2 | $5.7M | 0.01% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 29089Q105 · 2026Q2 | $4.1M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, EBS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on EBS
- EBS share buybacks Cash paid for repurchases, shares bought and program authorizations, from SEC filings.
- EBS insider trading clusters Three or more insiders filing the same direction within 30 days, from SEC Form 4.
- EBS against its peers Growth, margins and valuation beside the industry median, from annual SEC filings.
EBS mentioned in Kresmion daily briefs
EBS against its peers
EBS's operating margin of 13.5% ranks in the 88th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | EBS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 743M USD | 34.3M USD | 96 | 12 |
| Gross margin | 56.1% | n/a | n/a | 1 |
| Operating margin | 13.5% | -154.7% | 88 | 11 |
| Net margin | 7.1% | -157.4% | 88 | 11 |
| Return on equity | 10.1% | -40.1% | 91 | 16 |
| P / E | 6.5x | n/a | n/a | 0 |
Peers (20): PRLD, TTRX, KYTX, XFOR, ARCT, CYDY, ENTA, GALT, BNTC, IRD, NWBO, NAUT, SABS, AVTX, OBIO, AGEN, FENC, CTNM, QTTB, TECX. Left out: AGMB (no annual filing), VOGX (no annual filing), EIKN (no annual filing), SCTX (no annual filing), VCRE (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (EBS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in EBS on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on EBS in the last 180 days.
Upstream: SEC EDGAR filings for EBS
Kresmion, "Emergent BioSolutions Inc. (EBS) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/EBS. Upstream data: SEC EDGAR filings for EBS.
Link to this data (HTML):
<a href="https://kresmion.com/research/EBS">Emergent BioSolutions Inc. (EBS) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow EBS on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to EBS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.